Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PALB2 A38V |
| Therapy | Olaparib |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PALB2 A38V | Advanced Solid Tumor | no benefit | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, expressing PALB2 A38V did not confer sensitivity to Lynparza (olaparib)-induced growth inhibition in TP53 and PALB2 double knock-out mouse embryonic stem cells in culture (PMID: 33811135). | 33811135 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (33811135) | Characterisation of protein-truncating and missense variants in PALB2 in 15 768 women from Malaysia and Singapore. | Full reference... |